Literature DB >> 26369540

The Safety and Efficacy of Narrow Band Ultraviolet B Treatment in Dermatology: A Review.

Anna Sokolova1, Andrew Lee2,3, Saxon D Smith4,5.   

Abstract

Narrow-band ultraviolet B (NBUVB) phototherapy is an important treatment modality in dermatology. The most common dermatological indications for NBUVB include psoriasis, atopic dermatitis and vitiligo; however, it has been found to be an effective and well-tolerated treatment option in various other dermatoses. The efficacy of NBUVB phototherapy compares favorably with other available photo(chemo)therapy options and its efficacy is further augmented by a number of topical and systemic adjuncts. The long-term safety of NBUVB phototherapy remains to be fully elucidated; however, available data now suggest that it is safe and well-tolerated. The objective of this review was to summarize the current understanding of the safety and efficacy of NBUVB phototherapy in dermatology.

Entities:  

Mesh:

Year:  2015        PMID: 26369540     DOI: 10.1007/s40257-015-0151-7

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  3 in total

1.  Dermoscopic changes in melanocytic nevi covered with both opaque tape and sunscreen cream during narrowband ultraviolet B therapy.

Authors:  Derya Ök Kekeç; Nida Kaçar; Işıl Kılınç Karaarslan
Journal:  Dermatol Pract Concept       Date:  2018-04-30

Review 2.  Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.

Authors:  Mamitaro Ohtsuki; Hiroshi Morimoto; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2018-06-21       Impact factor: 4.005

3.  Effectiveness of narrowband UVB phototherapy and psoralen plus UVA photochemotherapy in the treatment of generalized lichen planus: Results from a large retrospective analysis and an update of the literature.

Authors:  Benedikt Weber; Elias Marquart; Sonja Radakovic; Adrian Tanew
Journal:  Photodermatol Photoimmunol Photomed       Date:  2021-08-11       Impact factor: 3.254

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.